Introduction
Drug associated muscle adverse reaction (DAMAR) refers to damage of
muscle tissues and cells associated with drugs, includes myalgia,
myopathy, myositis, myonecrosis and rhabdomyolysis[1]. The serious adverse reaction, rhabdomyolysis,
can cause acute renal failure or electrolyte disorders[2,3], therefore the monitoring of DAMAR is an
important composition of drug safety evaluation. DAMAR exists widely
among statins [4], often called statin associated
muscle symptoms (SAMS), the clinical features of which had been focused
and studied, leading to modification of drug labels[5]. Many kinds of drugs can cause DAMAR besides
statins with plenty of case reports [6,7] but
lacking in research of clinical features and incidence.
In this study, we performed real world safety evaluation using muscle
adverse reaction module[8] in adverse drug event
active surveillance and assessment system-Ⅱ
(ADE-ASAS-Ⅱ)[9]. To provide references to
clinical practice, we retrospectively analysis incidence, clinical
features, and associated drugs of DAMAR.